[MNK] Mallinckrodt plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 53.18 Change: 1.16 (2.23%)
Ext. hours: 53 Change: -0.18 (-0.34%)

chart MNK

Refresh chart

Strongest Trends Summary For MNK

MNK is in the medium-term down -53% in 5 months. In the long-term down -88% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provi

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 39.32% Sales Growth - Q/Q5.03% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.44% ROE-3.57% ROI-1.9%
Current Ratio2.86 Quick Ratio2.41 Long Term Debt/Equity2.75 Debt Ratio0.15
Gross Margin50.09% Operating Margin-4.3% Net Profit Margin-5.75% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40.6 M Cash From Investing Activities-53 M Cash From Operating Activities365.5 M Gross Profit488.5 M
Net Profit98.8 M Operating Profit95.2 M Total Assets12.81 B Total Current Assets2.22 B
Total Current Liabilities775.7 M Total Debt3.99 B Total Liabilities7.63 B Total Revenue909.9 M
Technical Data
High 52 week36.08 Low 52 week11.99 Last close17.73 Last change-5.03%
RSI10.84 Average true range1.23 Beta1.35 Volume1.2 M
Simple moving average 20 days-20.82% Simple moving average 50 days-31.17% Simple moving average 200 days-21.28%
Performance Data
Performance Week-14.96% Performance Month-42.55% Performance Quart-40.26% Performance Half-12.18%
Performance Year-25.19% Performance Year-to-date-21.41% Volatility daily3.48% Volatility weekly7.78%
Volatility monthly15.95% Volatility yearly55.24% Relative Volume178.31% Average Volume2.26 M
New High New Low

News

2019-01-19 08:01:57 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2019-01-16 17:06:39 | 5 Health Care Stocks in Gurus' Portfolios

2019-01-15 08:03:53 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2019-01-14 12:09:00 | House Democrats launch drug-pricing probe into a dozen major health-care companies

2019-01-14 12:03:40 | The Mallinckrodt Spinoff Is a Short-Term Win

2019-01-14 06:45:00 | Mallinckrodt plc To Report Earnings Results For Fourth Quarter And Fiscal 2018

2019-01-11 09:30:02 | MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

2019-01-10 14:54:07 | Akorn AKRX Gets FDA Warning Letter for Illinois Facility

2019-01-03 17:43:10 | Cara CARA Up on IDMC's Recommendation to Continue Trial

2019-01-03 06:30:00 | Data on Use of Mallinckrodt's H.P. Acthar® Gel Repository Corticotropin Injection in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation

2019-01-02 06:58:11 | Heron Gains on Priority Review Designation for Pain Drug

2018-12-26 08:02:06 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2018-12-24 09:29:02 | Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

2018-12-24 08:01:51 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2018-12-21 06:45:00 | Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy

2018-12-21 06:00:00 | Year in review: Hospital shakeups, urgent care invasion lead health care news cycle

2018-12-19 19:40:56 | [$$] Federal Judge Strikes Down New York Tax on Opioid Industry

2018-12-19 18:22:46 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2018-12-19 16:30:40 | Judge blocks New York from enforcing opioid surcharge on companies

2018-12-18 08:01:58 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2018-12-17 06:30:00 | Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference

2018-12-15 22:56:24 | Is Mallinckrodt Public Limited Company MNK A Good Stock To Buy?

2018-12-13 09:26:02 | Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

2018-12-12 10:17:23 | FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation

2018-12-12 07:54:07 | FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

2018-12-12 07:45:44 | [$$] FDA Doesn't Approve Mallinckrodt's Abuse-Deterrent Roxicodone

2018-12-12 06:58:00 | Mallinckrodt shares slide 4% premarket after pain treatment approval delayed

2018-12-12 06:54:30 | FDA declines to approve reformulated Mallinckrodt opioid

2018-12-12 06:45:00 | Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® Oxycodone Hydrochloride

2018-12-07 15:14:08 | Mallinckrodt MNK to Separate Generics & Branded Businesses

2018-12-07 14:25:58 | Mallinckrodt company that remains in St. Louis faces big threats

2018-12-07 11:28:11 | Investors Hope Cleaving of Mallinckrodt Provides Meaty Returns

2018-12-06 23:59:08 | Mallinckrodt plc -- Moody's: Mallinckrodt's proposed specialty generics spin-off is credit negative

2018-12-06 14:29:37 | Mallinckrodt to spin off generic drugs business; specialty drugs to be based in New Jersey

2018-12-06 11:37:14 | Mallinckrodt to spin off generics business, but to keep options open

2018-12-06 09:07:00 | Shares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-off

2018-12-06 06:00:00 | Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders

2018-12-04 10:48:43 | Is Mallinckrodt Public Limited Company NYSE:MNK A Volatile Stock?

2018-11-26 16:08:00 | Why Mallinckrodt Stock Sank Today

2018-11-26 15:59:58 | 5 Top Stock Trades for Tuesday: GE, GM and Cyber Monday

2018-11-26 14:20:00 | Mallinckrodt plc MNK Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

2018-11-19 12:33:00 | Mallinckrodt Stock Can Rally Another 27%, Says Analyst

2018-11-19 11:15:18 | Canaccord Turns Bullish On Mallinckrodt: 4 Reasons Why

2018-11-19 07:32:28 | How Is Salix Pharmaceuticals Positioned in November?

2018-11-16 08:08:31 | The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

2018-11-15 16:09:09 | Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug

2018-11-15 08:45:00 | Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP — Fundamental Analysis, Key Performance Indications

2018-11-15 08:10:31 | The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

2018-11-14 17:08:00 | Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® Oxycodone Hydrochloride

2018-11-14 08:17:55 | The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut